FIGURE 3.

Growth of grant funding and articles in the top 10 areas of LBD research. Lysosomal Glucocerebrosidase activity/functions excluded from plot due to too low n to calculate CAGR; Caregiving/cognition rehab excluded due to out of scope of workshop focus. Growth measured by CAGR. CAGR values for ‘3′ calculated using 2017–2021 data. Projects under “Alpha‐synuclein Targeting Therapeutic Approaches” categorized as “Drug discovery/drug target identification.” Source: BCG analysis and Lee et al.^7. BCG, Boston Consulting Group; CAGR, compound annual growth rate; LBD, Lewy body dementia